We are live on ! Find out more
DMRA

Damora Therapeutics, Inc. Ordinary Shares

25 hedge funds and large institutions have $21M invested in Damora Therapeutics, Inc. Ordinary Shares in 2022 Q1 according to their latest regulatory filings, with 3 funds opening new positions, 3 increasing their positions, 8 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more funds holding

Funds holding: 2525 (0)

0% more first-time investments, than exits

New positions opened: 3 | Existing positions closed: 3

0.08% less ownership

Funds ownership: 1.59%1.51% (-0.08%)

31% less capital invested

Capital invested by funds: $30.5M → $21M (-$9.43M)

63% less repeat investments, than reductions

Existing positions increased: 3 | Existing positions reduced: 8

Holders
25
Holders Change
Holders Change %
0%
% of All Funds
0.39%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
3
Increased
3
Reduced
8
Closed
3
Calls
Puts
Net Calls
Net Calls Change
Name Holding Trade Value Shares
Change
Change in
Stake
Susquehanna International Group
26
Susquehanna International Group
Pennsylvania
-$48K -639 Closed
MIFH
27
Migdal Insurance & Financial Holdings
Israel
-$10K -125 Closed
Simplex Trading
28
Simplex Trading
Illinois
-$1.07K -19 -86%

DMRA Hedge Fund Activity: Q1 2022 in Review

25 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in Damora Therapeutics, Inc. Ordinary Shares (DMRA) for Q1 2022, worth a combined $21M — down 31% from $30.5M a quarter earlier.

Fund positioning in DMRA was balanced in Q1 2022: 3 funds opened new positions, 3 closed out, 3 added to existing stakes and 8 trimmed.

The largest buyer was Marquette Asset Management, adding an estimated $20.8K. The largest seller was Anson Funds Management, exiting entirely with an estimated $556K sold.

  • 25 institutional investors held Damora Therapeutics, Inc. Ordinary Shares (DMRA) as of Q1 2022, unchanged from Q4 2021.
  • Funds reported $21M of Damora Therapeutics, Inc. Ordinary Shares stock for Q1 2022, down 31% quarter-over-quarter.
  • 3 funds opened new Damora Therapeutics, Inc. Ordinary Shares positions in Q1 2022 and 3 closed out, a net change of 0 holders.
  • The largest Damora Therapeutics, Inc. Ordinary Shares buyer in Q1 2022 was Marquette Asset Management, an estimated $20.8K added.
  • The largest Damora Therapeutics, Inc. Ordinary Shares seller in Q1 2022 was Anson Funds Management, an estimated $556K sold.

Based on aggregated 13F filings for Q1 2022.